EU Potential Changes to TPD
Blog articles
In April 2026, the European Commission published its evaluation of the Tobacco Products Directive and Tobacco Advertising Directive (TPD) and Tobacco Advertising Directive (TAD). The evaluation concluded that, while the existing framework has made a positive contribution to the protection of public health, it is increasingly challenged by the emergence and growing use of novel tobacco and nicotine products.
Toxicology and Regulatory News October 2026: Top 5 Takeaways
Blog articles
2 Oct 2026
October's Toxicology and Regulatory News brings together key developments across bioavailability adjustments, chemical safety, AI, particulate matter and more.
Toxicology and Regulatory News September 2026: Top 5 Takeaways
Blog articles
3 Sept 2026
September's Toxicology and Regulatory News brings together key developments from the WHO, EFSA, ECHA, OECD and more.
Toxicology and Regulatory News August 2026: Top 5 Takeaways
Blog articles
3 Aug 2026
August’s Toxicology and Regulatory News brings together key developments across medical device toxicology, chemical safety, food contact materials and occupational exposure.
Toxicology and Regulatory News July 2026: Top 5 Takeaways
Blog articles
10 Jul 2026
Catch up on July 2026 toxicology news, including updates on medical device constituents, glyphosate, FCMs, animal testing and wood dust.
Toxicology and Regulatory News June 2026: Top 5 Takeaways
Blog articles
15 Jun 2026
Stay up to date with the biggest takeaways from toxicology news in June 2026, including the EFSA’s evaluation of glycerol, the SCCS’s opinions on silver, CBD and acetophenone in cosmetics, and more.
Toxicology and Regulatory News May 2026: Top 5 Takeaways
Blog articles
18 May 2026
Stay up to date with the biggest takeaways from toxicology news in May 2026, including the EC’s evaluation of the Tobacco Products Directive and investigations into ethylene glycol’s developmental and reproductive toxicity.
Bisphenol A (BPA) Controversy
Blog articles
It is a truth not always recognised that toxicological hazard and risk assessment as currently practiced is a ball-park science, and a health criteria value – a Tolerable Daily Intake (TDI), a Permitted Daily Exposure (PDE) or similar – quoted to 2 significant figures is probably one significant figure more than the data really can confidently support. Occasionally practitioners will let the mask slip...
NAMs for NGRAs
Blog articles
Traditionally, toxicological risk assessment has involved identifying a point of departure (PoD) such as a NOAEL or LOAEL in a study of small creatures, adjusting it to be relevant to humans (to derive, for example, a TI or DNEL), and then calculating the margin of safety to a measured or estimated external exposure. As part of this process, toxicologists have to account for the uncertainties that arise in moving from the species, route and duration of the laboratory animal study to the real human world.
FDA memoranda: genotoxicity and carcinogenicity assessments of ENDS
Blog articles
As discussed in a previous blog post, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has issued several “scientific policy memoranda” that provide some great insights into the Agency’s evaluation process. In June 2024, the FDA made two new memos available that relate to the genotoxicity and carcinogenicity assessment of chemical constituents of Electronic Nicotine Delivery Systems (ENDS).